HLX35 binds EGFR on tumor cells and 4-1BB on activated T/NK cells, providing localized 4-1BB costimulation that enhances effector function and leads to T/NK cell–mediated lysis (perforin/granzyme) of EGFR+ cells; concurrent EGFR blockade adds antiproliferative effects.